Venus Forays Into Singapore's Topical Pain Management Market with Marketing Approval, Patent for Trois

• Company holding talks with various pharmaceutical firms for tie-ups

• Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffers from symptoms of osteoarthritis

• Global size of topical pain management market is $4 billion and Trois has the potential of becoming a US $250-million product once launched internationally

• Trois is 30% more effective than conventional products, as proven by a series of toxicity and safety studies, has 150% enhanced retention for longer effect, improved relief

Venus Remedies Ltd, a global research-driven pharmaceutical company, has entered Singapore's topical pain management market with a marketing authorisation and patent for its herbal nanotechnology-based pain reliever Trois. The company is holding talks with various pharmaceutical firms for tie-ups to market Trois in Singapore.

Hailing the achievement, Venus Remedies Chairman and Managing Director Pawan Chaudhary said, "This is a great opportunity for us to capture a sizeable share in this segment of the Singapore pharma market. Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffers from symptoms of osteoarthritis."

Chaudhary said the worldwide size of the topical pain management market is $4 billion, and, going by global projections, Trois has the potential of becoming a US $250-million product once launched internationally.

A product for topical use, Trois provides quick and lasting relief to patients suffering from rheumatic disorders, low back pain, osteoarthritis, rheumatoid arthritis, gout, knee pain, ankylosing spondylitis, fibromyalgia and pain originating from muscles and tendons. Currently, more than 1.5 billion people worldwide suffer from chronic pains of varying degree.

"Trois is the safest known topical product for management of pain and inflammation associated with rheumatic disorders. It is 30% more effective than conventional products, as proven by a series of toxicity and safety studies. It has 150% enhanced retention for longer effect, improved relief and better mobility," said Dr Manu Chaudhary, Joint Managing Director and Director, Research, Venus Remedies.

A pioneer in translational medicine, Venus has filed the product, process and use patent for Trois in 46 countries. While the company has already received patents from South Africa, New Zealand and now Singapore, it is on the verge of getting patent grants from the US, Canada and Europe.

Acknowledged as the Best Innovation for 2011 jointly by the Lockheed Martin Foundation, IC2 Texas, US, Indo-US Science and Technology Forum and the Department of Science and Technology, Government of India, Trois was launched in India last year. Having received a tremendous response from doctors and an encouraging feedback from patients in India, Trois is set to be a blockbuster product in the next few years.

The unique proposition of Trois is that it acts simultaneously on multiple inflammation-causing pathways to provide relief from pain and inflammation of multiple origins with very high efficacy as the particle size is less than the size of skin pores, thus making it easier to penetrate. Trois acts by selective cox-2 inhibition and inhibits transient receptor potential (TRP) activation and nociceptor stimulation (central and peripheral), thereby preventing cartilage degradation and bone erosion.

About Venus Remedies:

Venus Remedies, headquartered in Panchkula, Haryana (India), is among the 10 leading fixed-dosage injectable manufacturers in the world. The company has three manufacturing units, in Panchkula, Baddi (both India) and Werne (Germany) and 11 overseas marketing offices, including a presence in the US and Germany.

The manufacturing units are certified for ISO 9001, ISO 14001, ISO 18001 and OHSAS. The company has also been approved by EUROPEAN-GMP, WHO-GMP, Latin American GMP (INVIMA), Ukrainian GMP, Zimbabwe GMP, Uganda GMP, Syrian GMP, Columbian GMP, Kenya GMP, Yemen GMP, Saudi Arabian GMP and Iranian GMP, among others.

Venus Remedies has been ranked 107th in Asia (source: Bio Spectrum Asia) and among the 500 largest pharmaceutical manufacturing companies in the world (source: Plimsoll Worldwide Business Intelligence Report).

Venus has won over 102 patents for its innovative research products worldwide. The company has presence in 60 countries and covers more than 75 products.

About Venus Medicine Research Centre:

The Venus Medicine Research Centre (VMRC) located at Baddi, Himachal Pradesh, is a fully equipped interdisciplinary drug discovery and development centre, duly approved by the Department of Scientific and Industrial Research (DSIR), Government of India.

The VMRC is committed to developing therapeutics to meet the challenges of antimicrobial resistance, targetted delivery of anticancer drugs and to provide solution to unmet medical needs in area of pain management. It has come up with many solutions for chronic diseases and has been awarded as the best innovator in hat trick by Indo US Science & Technology forum, Govt of India. It has achieved significant breakthrough in small molecule research for developing products helpful in combating antimicrobial resistance, utilising novel targets and adjuvants which synergise with other antibiotics and minimising potential for resistance for notable resistance barriers like ESBLs, "plasmid encoded carbapenem resistant metalo-beta-lactamases", methicillin-resistant staphylococcus aureus (MRSA) and bacterial biofilms.

For further information, please contact:

Amardeep Singh Tiwana

Adfactors PR Pvt Ltd

Mobile: 9814046480

[email protected]